ExonHit Announces the Inclusion of Proprietary Lead Compounds into Allergan Collaboration
News Feb 24, 2010
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
"We are very fortunate to have a strong and productive partnership with Allergan, which allows both companies to take advantage of opportunities to shorten development timelines and rapidly move to create new shared products and value," stated Loic Maurel M.D., President of ExonHit Therapeutics' Management Board.
ExonHit will continue to lead the medicinal chemistry effort related to this target. The compounds are active against a new enzyme target potentially useful for therapeutic development in ophthalmology and neurodegenerative indications.
Milestone and royalty terms of the existing collaboration agreement will apply to these compounds and the products derived from them.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
Highly Potent Active Pharmaceutical Ingredients (HPAPI)
May 21 - May 22, 2018